Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates

A week ago, Beam Therapeutics Inc. (NASDAQ:BEAM) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Revenues of US$32m beat estimates by a substantial 160% margin. Unfortunately, Beam Therapeutics also reported a statutory loss of US$0.91 per share, which at least was smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGS:BEAM Earnings and Revenue Growth May 11th 2026

Taking into account the latest results, the 14 analysts covering Beam Therapeutics provided consensus estimates of US$74.0m revenue in 2026, which would reflect a substantial 55% decline over the past 12 months. Per-share losses are expected to explode, reaching US$4.41 per share. Before this earnings announcement, the analysts had been modelling revenues of US$48.3m and losses of US$4.33 per share in 2026. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady.

See our latest analysis for Beam Therapeutics

There were no major changes to the US$51.13consensus price target despite the higher revenue estimates, with the analysts seeming to believe that ongoing losses have a larger impact on the valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Beam Therapeutics analyst has a price target of US$80.00 per share, while the most pessimistic values it at US$26.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

Of course, another way to look at these forecasts is to place them into context against the industry itself. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 65% by the end of 2026. This indicates a significant reduction from annual growth of 26% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 22% annually for the foreseeable future. It's pretty clear that Beam Therapeutics' revenues are expected to perform substantially worse than the wider industry.

Story Continues

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. The consensus price target held steady at US$51.13, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Beam Therapeutics analysts - going out to 2028, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 2 warning signs for Beam Therapeutics (1 is a bit concerning!) that you need to be mindful of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments